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Abstract
Background—Despite a rise in the prevalence of hepatocellular carcinoma (HCC), data on 
HCC-related hospitalizations and financial burden are limited. The aim of this study was to 
evaluate temporal trends of HCC-related hospitalizations and evaluate its financial influence.
Materials and Methods—Patients with the diagnosis of HCC, as reported by International 
Classification of Diseases-Ninth Revision code, were identified from the National Inpatient 
Sample databases from 2002–2011. The national estimates of hospitalizations were derived using 
appropriate sample weights. The change in total average charges per each hospitalization over the 
study period was calculated after adjusting for inflation.
Results—Hospitalizations related to HCC have increased from 24,024 in 2002 to 50,609 in 2011. 
Of these admissions, HCC was the principal diagnosis in 10,762 and 16,350 subjects in 2002 and 
2011, respectively. Most were white males (male: 70%; white: 55%). The overall inpatient 
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mortality was significantly decreased from 13.5% in 2002 to 9.9% in 2011 (P < 0.01). The same 
trend was also observed for the length of hospital stay (6.5 versus 5.6 days in 2002 and 2011, 
respectively). The inflation-adjusted cost per hospitalization increased by approximately 47% 
during the study period.
Conclusions—Despite the decrease in mortality rate and length-of-stay, hospitalizations and 
financial burden associated with HCC continued to increase between 2002 and 2011 in the United 
States.
Key Indexing Terms
Hepatocellular carcinoma; Financial burden; National Inpatient Sample database; Hospitalizations; 
Liver cancer
BACKGROUND
Hepatocellular carcinoma (HCC) is responsible for significant morbidity and mortality in the 
United States, and it contributes a substantial economic burden to our healthcare system. 
Globally, HCC represents the fifth most prevalent cancer in men, the seventh most common 
cancer in women and is the third leading cause of cancer-related deaths worldwide.1 HCC 
occurs most frequently in the setting of chronic liver disease and cirrhosis and is most 
commonly associated with viral hepatitis.2,3 The incidence of HCC within the United States 
has been increasing over the past several decades, in parallel with the increase in hepatitis C 
virus and nonalcoholic steatohepatitis associated cirrhosis.2–6
The increase in HCC incidence continues to pose increasing demand for diagnosis, care and 
treatment.7 Therapeutic approaches for the treatment of HCC have evolved over the past few 
decades, including surgical resection, ablation therapy, transarterial chemoembolization and 
liver transplantation. These treatment modalities, while improving and benefitting patients 
with HCC, also lead to increase in cost and economic burden.2,6–8 Previous studies have 
evaluated the changing incidence and mortality rates of HCC over the years. However, few 
have studied the magnitude of change and its economic influence on inpatient 
hospitalization. The goals of this study are to determine the temporal trends of inpatient 
volume and evaluate the length-of-stay (LOS), total hospital charges and in-hospital 
mortality rate of HCC over the last decade.
MATERIALS AND METHODS
The Nationwide Inpatient Sample (NIS) from 2002–2011, developed by the Agency for 
Healthcare Research and Quality, was the primary data source for the analysis.9 These data 
are the largest all-payer inpatient care database in the United States, containing data on more 
than 7 million hospital stays annually from approximately 1,000 hospitals, constituting a 
20% stratified sample of all U.S. hospitals. All data were weighted using discharge-level 
values to produce 100% national estimates.
We identified patients with HCC by using International Classification of Diseases-Ninth 
Revision, Clinical Modification (ICD-9-CM) discharge diagnosis code 155.0. If this code 
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was listed in the first position, we considered HCC as the primary diagnosis or principal 
reason leading to hospitalization. Otherwise, we considered HCC as the secondary diagnosis 
for admission. In this scenario, patients were hospitalized for various causes, which may not 
be related to the underlying HCC.
The following variables were retrieved from the dataset: patient age, race, sex, household 
income, the geographic region of the hospitals and payers (i.e., Medicare, Medicaid and 
private). The types of hospitals were categorized into teaching or nonteaching, small or 
medium or large depending on the number of beds, and urban or rural location. Outcome-
measures were strati-fied for overall, primary and secondary diagnoses of HCC and included 
in-hospital mortality, LOS, financial charges and discharge disposition.
Additional data regarding radio or chemotherapy, liver biopsy, surgery and transplant 
interventions were retrieved using various ICD-9 codes. Proportions of HCC-related 
hospitalizations when intervention was performed and average cost of HCC-related 
hospitalizations with these interventions are provided in Supplementary Tables 1 and 2.
Statistical Analysis
All statistical analyses were performed using the sampling weights to obtain nationally 
representative estimates. Descriptive statistics were presented as a mean and frequencies for 
continuous and categorical variables, respectively. Annual rates of HCC-related 
hospitalization were calculated by dividing the number of inpatient admissions for HCC, 
stratified by primary or secondary diagnosis, by the total inpatient admissions in a given 
year. The financial charges per each hospitalization were calculated and additional cost of 
hospitalization per year was also calculated after adjusting for the inflation, using year 2002 
as the reference. The trend analysis was performed using simple linear regression. All 
analyses were performed using SAS 9.3 (Cary, NC), and the P < 0.05 was considered 
statistically significant.
RESULTS
National Estimates of HCC-Related Hospitalization Rates in the United States
We observed an increase in the rate for the overall HCC-related hospitalizations from 0.07% 
in 2002 to 0.14% in 2011 (P < 0.001). We observed no changes in the rate of admission 
when HCC was the primary diagnosis (0.03% in 2002 and 0.04% in 2011, P = 0.23). 
However, the rate of hospitalization when HCC was the secondary diagnosis increased 
significantly from 0.04% in 2002 to 0.09% in 2011 (P < 0.001, Table 1).
Demographics and Clinical Characteristics of Hospitalized Patients With HCC
The mean age of hospitalized patients with HCC was 60 years. Most were males (70–74%) 
and white (51–57%). In 2002, almost half of patients were classified as high income (fourth 
quartile), in contrast to only 19% in 2011 (Table 2).
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Sources of Admission and Types of Facilities for Hospitalized Patients With HCC
Hospitalized patients with HCC were admitted mainly through local emergency departments 
(Table 3). Most patients (61–70%) were admitted to teaching hospitals.
LOS, Discharge Patterns and Payers Related to HCC Hospitalizations
During the study period, there was a significant decrease in the average LOS for all 
hospitalized patients with HCC (6.5 days in 2002 to 5.6 days in 2011, P-value for trend 
<0.001). The same trend was observed when we analyzed the data for patients who were 
admitted with HCC as a primary diagnosis (7.1 days in 2002 to 5.9 days in 2011, P-value for 
trend <0.001). Interestingly, there were no differences in the LOS when we examined the 
data for those who were admitted with HCC as the secondary diagnosis (6.0 days in 2002 to 
5.5 days in 2011, P-value for trend =0.09, Table 4).
When we analyzed disposition data, we found a significant decrease in the percentage of 
patients who were discharged directly to home (62.6% in 2002 versus 55.4% in 2011, P-
value for trend =0.001). There was a shift in the discharge patterns toward skilled nursing 
facilities (9.5% in 2002 to 13.3% in 2011, P-value for trend <0.001) and home healthcare 
(11.6% in 2002 to 18.1% in 2011, P-value for trend <0.001).
The 2 main payers for the hospitalizations were Medicare (43–46%) and private insurance 
(27–33%). We observed a decrease in the percentage of patients with private insurance as 
the primary payer (32.2% in 2002 to 26.7% in 2011, P-value for trend =0.006, Table 4).
In-Hospital Mortality and Financial Charges for Hospitalizations Related to HCC
The overall in-hospital mortality of patients with HCC decreased significantly from 13.5% 
in 2002 to 9.9% in 2011 (P-value for trend <0.001). In the detailed analysis, in-hospital 
mortality rates significantly decreased regardless of whether patients were admitted with 
HCC as the primary (17% in 2002 to 9.8% in 2011, P-value for trend <0.001) or secondary 
diagnosis (10.7% in 2002 to 9.9% in 2011, P-value for trend =0.027, Table 4).
The overall financial charges per hospitalization increased substantially from $32,405 in 
2002 to $59,465 in 2011 (P-value for trend <0.001, Table 4). The increase was observed for 
the hospitalizations in which HCC was the primary diagnosis ($33,188 in 2002 to $64,397 in 
2011, P-value for trend <0.001) and secondary diagnosis ($31,767 in 2002 to $57,128 in 
2011, P-value for trend <0.001) (Table 4). After accounting for inflation, the additional cost 
per hospitalization increased by $15,153 in 2011 in reference to the charges in 2002 
(Figure).
DISCUSSION
Our study has a few notable findings, including a temporal increase in the overall HCC-
related hospitalization, particularly among those in whom HCC was the secondary 
diagnosis; a significant decrease in the percentage of hospitalized patients in the high-
income bracket; a significant decrease in the average LOS for all hospitalized patients with 
HCC, notably for those with HCC as the primary diagnosis; a shift in the discharge patterns 
toward skilled nursing facilities or home healthcare; a significant decrease in the in-hospital 
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mortality rate; and a significant increase in the financial charges related to hospitalization for 
patients with HCC.
The increase in the overall HCC-related hospitalizations, particularly among those with 
HCC as a secondary diagnosis likely reflects an increase in admissions due to underlying 
cirrhosis and end-stage liver disease– related complications such as hepatic encephalopathy, 
infection or sepsis, and acute renal failure.10,11
We found a significant decrease in the percentage of hospitalized patients in the high-income 
bracket. Previous studies have shown that a low socioeconomic status has been associated 
with chronic conditions including diabetes, obesity, metabolic syndrome, alcoholism and 
hepatitis C; all of which are risk factors for cirrhosis and have been shown to increase the 
risk for HCC.2,12,13 A plausible explanation for this is the expansion of accessibility to 
healthcare, and hence more patients in the lower income quartiles are being diagnosed and 
hospitalized with HCC and its complications. Furthermore, patients within a higher 
socioeconomic class are most likely to benefit from HCC screening and thus earlier 
detection. Early detection improves response to therapy, and thus reduces the complications 
and frequency of hospitalizations of these patients.14–16 However, the effect of early 
detection is expected to be small as our study population focused mainly on hospitalized 
patients with HCC, which are usually patients with advanced HCC.
We also observed a significant decrease in the average LOS for all hospitalized patients with 
HCC, notably for those with HCC as the primary diagnosis. The reasons behind this 
observation are not clear; however, it is plausible that this reflects the improvement in the 
treatment modalities for HCC and the improvement in the overall medical care for 
hospitalized patients with cirrhosis. These factors might also lead to a significant decrease in 
the in-hospital mortality rate for patients with HCC. Additionally, the shortened LOS might 
be due to a shift in transitioning care toward skilled nursing facilities and home healthcare 
once a patient can otherwise be discharged from the hospital. Use of these transition services 
has increased over the last decade.17
Despite the decrease in LOS and in-hospital mortality rate, the overall inflation-adjusted 
financial charges for hospitalizations related to HCC increased substantially during the study 
period, regardless of whether HCC was the primary or secondary cases for admission. This 
is likely due to the increase in the overall healthcare costs in the United States and the 
increased use of healthcare resources with access to more advanced and more expensive 
therapeutic modalities for HCC, such as liver transplantation, surgical resection, ablation 
therapy, etc. As seen in Supplementary Tables 1 and 2, the rate of such interventions appear 
to be decreasing over the past few years though the cost of hospitalization during which 
these interventions were performed seems to have increased significantly. These results 
should be interpreted cautiously owing to inherent limitations of the NIS database in 
providing details of each hospitalization. A vast majority of hospitalized patients with HCC 
were admitted to teaching hospitals in the urban area. This observation is not surprising 
because of the complexity of the disease and the treatment which ideally requires a 
multidisciplinary approach—services which can be provided more readily in tertiary or 
quaternary care centers.
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Our study has a few limitations. We used ICD-9 codes as the primary way to identify 
subjects with HCC. Additionally, NIS data does not include specifics on laboratory test 
results, imaging modalities, as well as the staging of the HCC. Thus, we cannot further 
analyze the effect of these parameters on LOS and in-hospital mortality. Lastly, the mortality 
rate reported herein is limited to only in-hospital mortality. We do not have information to 
extrapolate our results for the short- and long-term outcomes of these patients. Despite these 
shortcomings, our study is strengthened by the use of a large database that represents many 
US medical centers and patient populations to capture the inpatient burden of HCC.
CONCLUSIONS
Despite the decrease in in-hospital mortality rate and LOS, overall hospitalizations and 
financial burden associated with HCC continue to increase over the last decade in the United 
States.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE. 
(A) Hospitalization related to the diagnosis of HCC in the United States from 2002–2011; 
(B) additional total hospital charges after adjusting for inflation for the diagnosis of HCC 
from 2002–2011, using the charges in 2002 as the reference; (C) average length-of-stay of 
hospitalization for the diagnosis of HCC from 2002–2011; and (D) inpatient mortality for 
the diagnosis of HCC from 2002–2011. HCC, hepatocellular carcinoma.
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